RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings.
Journal
Journal of clinical psychopharmacology
ISSN: 1533-712X
Titre abrégé: J Clin Psychopharmacol
Pays: United States
ID NLM: 8109496
Informations de publication
Date de publication:
Historique:
entrez:
26
4
2020
pubmed:
26
4
2020
medline:
14
1
2021
Statut:
ppublish
Résumé
RE-KINECT (NCT03062033) was designed to assess the presence and impact of possible tardive dyskinesia (TD) in antipsychotic-treated outpatients. The study included adults with 3 or more months of lifetime antipsychotic exposure and 1 or more psychiatric disorder. Based on clinician observation and assessment, patients were assigned to cohort 1 (without involuntary movements or with non-TD involuntary movements) or cohort 2 (with involuntary movements confirmed by clinician as possible TD). Baseline assessments included the following: patient characteristics; location/severity of involuntary movements; and impact of possible TD on health-related quality of life, including the EuroQoL 5-Dimensions 5-Level questionnaire. Of 739 eligible patients, 204 (27.6%) had clinician-confirmed possible TD (cohort 2). Compared with cohort 1, patients in cohort 2 were significantly older (P < 0.0001), more likely to have schizophrenia or schizoaffective disorder (P < 0.0001) and longer lifetime exposure to antipsychotics (P < 0.0001), and less likely to be working or studying, based on clinician perception (P = 0.0010). Clinician- and patient-rated severity of possible TD movements was significantly correlated in each of 4 body regions (head/face, neck/trunk, upper extremities, lower extremities), for maximum severity in any region, and for total number of affected regions (P < 0.001 for all correlations). For the patient-rated EuroQoL 5-Dimensions 5-Level, the health state visual analog scale score was significantly lower (worse) in cohort 2 versus cohort 1 (66.8 vs 69.7; P = 0.0002), as was the utility index score (0.71 vs 0.76; P < 0.0175). Results from this real-world population indicate that TD occurs frequently and can significantly reduce quality of life in patients with a psychiatric disorder.
Sections du résumé
PURPOSE/BACKGROUND
OBJECTIVE
RE-KINECT (NCT03062033) was designed to assess the presence and impact of possible tardive dyskinesia (TD) in antipsychotic-treated outpatients.
METHODS/PROCEDURES
METHODS
The study included adults with 3 or more months of lifetime antipsychotic exposure and 1 or more psychiatric disorder. Based on clinician observation and assessment, patients were assigned to cohort 1 (without involuntary movements or with non-TD involuntary movements) or cohort 2 (with involuntary movements confirmed by clinician as possible TD). Baseline assessments included the following: patient characteristics; location/severity of involuntary movements; and impact of possible TD on health-related quality of life, including the EuroQoL 5-Dimensions 5-Level questionnaire.
FINDINGS/RESULTS
RESULTS
Of 739 eligible patients, 204 (27.6%) had clinician-confirmed possible TD (cohort 2). Compared with cohort 1, patients in cohort 2 were significantly older (P < 0.0001), more likely to have schizophrenia or schizoaffective disorder (P < 0.0001) and longer lifetime exposure to antipsychotics (P < 0.0001), and less likely to be working or studying, based on clinician perception (P = 0.0010). Clinician- and patient-rated severity of possible TD movements was significantly correlated in each of 4 body regions (head/face, neck/trunk, upper extremities, lower extremities), for maximum severity in any region, and for total number of affected regions (P < 0.001 for all correlations). For the patient-rated EuroQoL 5-Dimensions 5-Level, the health state visual analog scale score was significantly lower (worse) in cohort 2 versus cohort 1 (66.8 vs 69.7; P = 0.0002), as was the utility index score (0.71 vs 0.76; P < 0.0175).
IMPLICATIONS/CONCLUSIONS
CONCLUSIONS
Results from this real-world population indicate that TD occurs frequently and can significantly reduce quality of life in patients with a psychiatric disorder.
Identifiants
pubmed: 32332461
doi: 10.1097/JCP.0000000000001201
pii: 00004714-202005000-00007
pmc: PMC7190052
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
259-268Références
Acta Psychiatr Scand. 2011 Nov;124(5):357-62
pubmed: 21838740
BMC Neurol. 2019 Jul 20;19(1):174
pubmed: 31325958
Drugs. 2016 May;76(7):779-87
pubmed: 27091214
J Neurol Sci. 2018 Jun 15;389:1-3
pubmed: 29449008
J Neurol Sci. 2018 Jun 15;389:21-27
pubmed: 29439776
J Clin Psychiatry. 2008 Oct;69(10):1580-8
pubmed: 19192441
Health Aff (Millwood). 2009 Sep-Oct;28(5):w770-81
pubmed: 19622537
Psychosomatics. 1984 Feb;25(2):135-8
pubmed: 6142494
Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:89-95
pubmed: 8923116
Biol Psychiatry. 1984 Mar;19(3):441-4
pubmed: 6144331
Curr Pharm Des. 2015;21(23):3280-97
pubmed: 26088115
Acta Psychiatr Scand. 1996 Aug;94(2):118-24
pubmed: 8883573
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Clin Psychiatry. 1986 Feb;47(2):75-7
pubmed: 2867994
J Clin Psychiatry. 2017 Mar;78(3):e264-e278
pubmed: 28146614
PLoS One. 2012;7(9):e44613
pubmed: 22970266
Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):177-84
pubmed: 21254289
Arch Gen Psychiatry. 1982 Apr;39(4):486-7
pubmed: 6121550
Psychiatr Clin North Am. 2016 Sep;39(3):391-411
pubmed: 27514296
Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
pubmed: 15000267
J Clin Psychiatry. 2018 May/Jun;79(3):
pubmed: 29742330
J Neurol Sci. 2018 Jun 15;389:4-9
pubmed: 29454494
Drug Des Devel Ther. 2013 Nov 06;7:1329-40
pubmed: 24235816
Hosp Community Psychiatry. 1994 Apr;45(4):343-6
pubmed: 7912689
Schizophr Res. 2011 Sep;131(1-3):101-4
pubmed: 21741216
J Clin Psychiatry. 2018 Mar 20;79(2):
pubmed: 29570969
Arch Gen Psychiatry. 1985 Sep;42(9):866-71
pubmed: 2864030
Psychosomatics. 1985 Apr;26(4):305-7, 310, 312-3
pubmed: 2859630
CNS Spectr. 2018 Dec;23(6):370-377
pubmed: 28877766
Curr Opin Psychiatry. 2019 May;32(3):179-184
pubmed: 30720484
Clin Ther. 2013 Dec;35(12):1867-75
pubmed: 24119767
Am J Psychiatry. 1998 Nov;155(11):1521-8
pubmed: 9812112
Tremor Other Hyperkinet Mov (N Y). 2013 Jul 12;3:
pubmed: 23858394